Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

2(40.0%)

Phase 2

2(40.0%)

Phase 1

1(20.0%)

5Total

Phase 3(2)

Phase 2(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02975141Phase 1Unknown

Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer

Role: lead

NCT03263663Unknown

Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model

Role: lead

NCT01728818Phase 2Unknown

Afatinib as Cancer Therapy for Exocrine Pancreatic Tumours

Role: lead

NCT00433927Phase 3Unknown

5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

Role: lead

NCT00440167Phase 3Unknown

Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine

Role: lead

NCT01384994Phase 2Unknown

Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients

Role: lead

All 6 trials loaded